Anna Duarri Piqué Institutions of which they are part Main researcher Ophtalmology Vall Hebron Institut de Recerca Email Anna Duarri Piqué Email Institutions of which they are part Main researcher Ophtalmology Vall Hebron Institut de Recerca
Research lines CeO2 Nanoparticles-assisted stem-based cell therapy: an innovative nanopharmaceutical approach to treat retinal degenerative diseases Chronic inflammation is now regarded as a major pathogenic pathway common in many different pathologies. This is the case of Age-related Macular Degeneration (AMD), a disease currently inevitable, orphan of treatment that represents a major cause of blindness in people over 50, and affects millions of people worldwide. The progression of AMD is associated to an increase of oxidative stress and inflammatory response in the eye leading to retinal cell death. Current studies suggest that antioxidant therapies for chronic inflammation treatment are a feasible objective to stop disease progression and represent a promising strategy to improve the therapeutic benefits of regenerative medicine to restore vision (since inflammation impedes proper regeneration). CeO2nanoparticles have a unique electronic structure that when reduced to the nanoscale, oxygen defects appear at their surface, behaving as sites for free radical scavenging. Thus, the main objective of CELLUX is to develop a novel pharmaceutical-based CeO2 nanoparticles eye drops to treat AMD that in combination with stem cell-based therapeutic strategies, will not only stop degeneration but restore vision. The accomplishment of the objectives will represent a significant advance in the current concept of nanomedicine to treat degenerative diseases. IP: Anna Duarri Piqué Projects BIOBANCOS Y BIOMODELOS IP: Isabel Novoa Garcia Collaborators: Joaquim Vives Armengol, Anna Duarri Piqué, Eva Colas Ortega, Oriol Bestard Matamoros, Marta Rosal Fontana, Carmen Espejo Ruiz, Marielle Esteves Coelho, Juan Jose Gonzalez Lopez, Sheyla Pascual Martín, Alejandro Tomasello Weitz Funding agency: Instituto de Salud Carlos III Funding: 137460 Reference: PT23/00040 Duration: 01/01/2024 - 31/12/2026 Administración tópica (colirio) de sitagliptina como tratamiento para la retinopatía diabética proliferativa (TopSit@) IP: Rafael Simó Canonge Collaborators: Anna Duarri Piqué, Cristina Hernández Pascual, Hugo Ramos Abellan, Patricia Bogdanov Baruj Funding agency: Ministerio de Ciencia e Innovación-MICINN Funding: 128570 Reference: PDC2022-133991-I00 Duration: 01/12/2022 - 30/11/2024 Oftalmologia IP: José García Arumí Collaborators: Javier José Puig Galy, Anna Duarri Piqué, Ana Boixadera Espax, Jaume Rigo Quera, Helena Isla Magrané, Claudia Garcia-Arumí Fusté, Miguel Angel Zapata Victori, Sara Martin Nalda, Laura Natalia Distefano, Randa Falah Funding agency: Agència Gestió Ajuts Universitaris i de Recerca Funding: 0.01 Reference: 2021 SGR 00994 Duration: 01/01/2022 - 30/06/2025 RETVISION: Del diagnóstico genético molecular a las terapias avanzadas para tratar las enfermedades degenerativas de la retina. IP: José García Arumí Collaborators: María Antolín Mate, Anna Duarri Piqué, Helena Isla Magrané, Claudia Garcia-Arumí Fusté, Miguel Angel Zapata Victori, Laura Natalia Distefano, Randa Falah Funding agency: Instituto de Salud Carlos III Funding: 123420 Reference: PI22/01747 Duration: 01/01/2023 - 31/12/2025 Pagination Current page 1 Page 2 Next page › Last page »
